NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021. Journal of the National Comprehensive Cancer Network : JNCCN Pollyea, D. A., Bixby, D. n., Perl, A. n., Bhatt, V. R., Altman, J. K., Appelbaum, F. R., de Lima, M. n., Fathi, A. T., Foran, J. M., Gojo, I. n., Hall, A. C., Jacoby, M. n., Lancet, J. n., Mannis, G. n., Marcucci, G. n., Martin, M. G., Mims, A. n., Neff, J. n., Nejati, R. n., Olin, R. n., Percival, M. E., Prebet, T. n., Przespolewski, A. n., Rao, D. n., Ravandi-Kashani, F. n., Shami, P. J., Stone, R. M., Strickland, S. A., Sweet, K. n., Vachhani, P. n., Wieduwilt, M. n., Gregory, K. M., Ogba, N. n., Tallman, M. S. 2021; 19 (1): 16–27


The NCCN Guidelines for Acute Myeloid Leukemia (AML) provide recommendations for the diagnosis and treatment of adults with AML based on clinical trials that have led to significant improvements in treatment, or have yielded new information regarding factors with prognostic importance, and are intended to aid physicians with clinical decision-making. These NCCN Guidelines Insights focus on recent select updates to the NCCN Guidelines, including familial genetic alterations in AML, postinduction or postremission treatment strategies in low-risk acute promyelocytic leukemia or favorable-risk AML, principles surrounding the use of venetoclax-based therapies, and considerations for patients who prefer not to receive blood transfusions during treatment.

View details for DOI 10.6004/jnccn.2021.0002

View details for PubMedID 33406488